Prognostic factors and Doxorubicin involved in malignant progression of meningioma

Xulei Huo,Lairong Song,Ke Wang,Hongyi Wang,Da Li,Huan Li,Wei Wang,Yali Wang,Lei Chen,Zongmao Zhao,Liang Wang,Zhen Wu
DOI: https://doi.org/10.1038/s41598-023-28996-0
IF: 4.6
2023-04-08
Scientific Reports
Abstract:Meningioma was the most primary intracranial tumor, but the molecular characteristics and the treatment of malignant meningioma were still unclear. Nine malignant progression-related genes based prognostic signatures were identified by transcriptome analysis between benign meningioma and malignant meningioma. The external dataset GEO136661 and quantitative Real-time Polymerase Chain Reaction were used to verify the prognostic factors. has-miR-3605-5p, hsa-miR-664b-5p, PNRC2, BTBD8, EXTL2, SLFN13, DGKD, NSD2, and BVES were closed with malignant progression. Moreover, Doxorubicin was identified by Connectivity Map website with the differential malignant progression-related genes. CCK-8 assay, Edu assay, wound healing assay, and trans-well experiment were used to reveal that Doxorubicin could inhibit proliferation, migration and invasion of IOMM-Lee Cells.
multidisciplinary sciences
What problem does this paper attempt to address?